SS-31 Peptide Protects Diabetic Hearts by Preventing Mitochondrial Cell Death

Diabetic cardiomyopathy (DCM) is a severe and often fatal complication of diabetes, characterized by progressive damage to the heart muscle, ultimately leading to heart failure. A key contributor to DCM pathology is mitochondrial dysfunction and excessive oxidative stress, which can trigger various forms of cell death. Recent research has highlighted ferroptosis, a distinct iron-dependent form of programmed cell death, as a significant factor in the progression of DCM, yet its specific mitochondrial mechanisms and therapeutic targets remain underexplored. This study specifically addresses the role of mitochondrial-targeted therapies in mitigating ferroptosis in diabetic cardiomyopathy.

The study revealed that SS-31 treatment significantly improved cardiac function in diabetic mice, demonstrating a notable increase in left ventricular ejection fraction (LVEF) by ~18% compared to untreated diabetic controls (p<0.01). This improvement was accompanied by a substantial reduction in mitochondrial dysfunction and oxidative stress within the heart tissue. Crucially, SS-31 was found to activate mitoGPX4 (mitochondrial glutathione peroxidase 4), a pivotal enzyme that detoxifies lipid peroxides and protects against ferroptosis, with its activity increasing by ~55% in treated hearts. > SS-31 treatment effectively attenuated mitochondria-dependent ferroptosis in both high glucose-stressed cardiomyocytes and the hearts of diabetic mice, evidenced by a ~35% reduction in lipid peroxidation markers and a ~28% decrease in intracellular iron accumulation (p<0.001 for both). These findings underscore a direct protective mechanism of SS-31 against this specific form of cell death.